Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Sasha High. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sasha High or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Retatrutide - Top-Line Results from TRIUMPH 4

6:33
 
Share
 

Manage episode 523815772 series 3450393
Content provided by Sasha High. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sasha High or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.

Highlights:

  • Up to 28.7% weight loss (~71 lbs) over 68 weeks
  • 75% reduction in knee pain and major improvements in physical function
  • Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure

We also cover

  • Common side effects and safety signals
  • Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
  • A reality check on Canadian availability (likely 3+ years away)
  • A strong warning about illegal online sales and the risks of buying unregulated products

A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

  continue reading

165 episodes

Artwork
iconShare
 
Manage episode 523815772 series 3450393
Content provided by Sasha High. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sasha High or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.

Highlights:

  • Up to 28.7% weight loss (~71 lbs) over 68 weeks
  • 75% reduction in knee pain and major improvements in physical function
  • Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure

We also cover

  • Common side effects and safety signals
  • Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
  • A reality check on Canadian availability (likely 3+ years away)
  • A strong warning about illegal online sales and the risks of buying unregulated products

A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

  continue reading

165 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play